Table 2.
Clinical characteristics of 36 patients at baseline and after 24 weeks of treatment with dulaglutide
| Variables | Before treatment | After 24 weeks | p value |
|---|---|---|---|
| N | 36 | ||
| Sex (male/female) | 15/21 | ||
| Age (years) | 66.7 ± 11.1 | ||
| Duration of diabetes (years) | 17.9 ± 9.1 | ||
| BMI (kg/m2) | 28.7 ± 5.3 | 28.4 ± 5.3 | 0.0807 |
| SBP (mmHg) | 128.1 ± 11.7 | 126.5 ± 14.2 | 0.4410 |
| DBP (mmHg) | 71.5 ± 12.3 | 71.2 ± 11.2 | 0.8381 |
| FPG (mg/dL) | 137.5 ± 15.8 | 123.9 ± 15.2 | < 0.0001 |
| HbA1c (%) | 7.80 ± 0.99 | 7.25 ± 0.71 | < 0.0001 |
| AST (IU/L) | 25.1 ± 14.3 | 25.4 ± 18.0 | 0.8103 |
| ALT (IU/L) | 27.2 ± 14.0 | 29.1 ± 19.3 | 0.2952 |
| GGT (IU/L) | 46.0 ± 30.3 | 45.2 ± 32.3 | 0.7230 |
| LDL-C (mg/dL) | 90.5 ± 20.4 | 78.6 ± 18.0 | 0.0010 |
| HDL-C (mg/dL) | 46.9 ± 19.4 | 67.2 ± 18.5 | 0.1303 |
| TG (mg/dL) | 133.3 ± 52.3 | 131.5 ± 44.5 | 0.7734 |
| Creatinine (mg/dL) | 0.69 ± 0.22 | 0.71 ± 0.17 | 0.2374 |
| Uric acid (mg/dL) | 4.93 ± 1.35 | 4.66 ± 1.10 | 0.0818 |
| Antidiabetic medications (n) | |||
| Sulfonylurea | 22 | ||
| Metformin | 14 | ||
| Thiazolidinedione | 5 | ||
| DPP-4 inhibitor | 36 | ||
| SGLT2 inhibitor | 17 | ||
| Insulin injection | 19 | ||
| Hypolipidemic agents (n) | |||
| Statins | 26 | ||
| Fibrates | 4 | ||
| Antihypertensive agents (n) | |||
| ARBs/ACEIs | 26 | ||
| CCBs | 18 | ||
| β-blockers | 3 | ||
| Diuretics | 12 | ||
Data are mean ± SD
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, HbA1c hemoglobin A1c, AST aspartate aminotransferase, ALT alanine aminotransferase, GGT γ-glutamyltransferase, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, TG triglycerides, DPP-4 dipeptidyl peptidase-4, SGLT2 sodium-glucose co-transporter-2, ARBs angiotensin II receptor blockers, ACEIs angiotensin-converting enzyme inhibitors, CCBs calcium channel blockers